Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Qianyi Xie"'
Publikováno v:
2022 Joint Conference of the European Frequency and Time Forum and IEEE International Frequency Control Symposium (EFTF/IFCS).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d6fbcadcba6ea0c9456c2ba071b2c2e
https://doi.org/10.1109/eftf/ifcs54560.2022.9850437
https://doi.org/10.1109/eftf/ifcs54560.2022.9850437
Publikováno v:
Research Series on the Chinese Dream and China’s Development Path ISBN: 9789811687884
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed3b427cbcaac3872d1c565abad5eb96
https://doi.org/10.1007/978-981-16-8789-1_11
https://doi.org/10.1007/978-981-16-8789-1_11
Autor:
Peng Xiao, Longyu Jin, Yicai Liu, Xiaozhi Li, Wei He, Suo Liu, Zhao Zhu, Hao Tang, Qianyi Xie, Yuchao Ma, Yinji Chen, Wei Feng, Yanfei Chai, Zhibin Jiang
Publikováno v:
Cancer Science
Osimertinib is a third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) for lung adenocarcinoma (LUAD) harboring activating mutations, but patients ultimately develop acquired resistance. Circular RNAs are involved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf6c5232e660a5a065572fbb539a7b3c
https://pubmed.ncbi.nlm.nih.gov/34706132
https://pubmed.ncbi.nlm.nih.gov/34706132
Publikováno v:
Cancer Science. 109:1775-1786
Gefitinib has been widely used in the first-line treatment of advanced EGFR-mutated non-small-cell lung cancer (NSCLC). However, many NSCLC patients will acquire resistance to gefitinib after 9-14 months of treatment. This study revealed that Krüppe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b40f42a3ce5c6fa62088271a66a6f7f2
https://doi.org/10.1111/cas.13601
https://doi.org/10.1111/cas.13601
Autor:
Wei Fen, Chunyun Li, Qianyi Xie, Dianjun Wang, Linfei Yang, Zhibin Jiang, Longyu Jin, Lihua Huang, Ying Ji
Publikováno v:
Experimental and therapeutic medicine. 16(4)
The aim of the present study was to investigate the protective effect of eugenol on the transplanted heart and explore its mechanisms of action. Male Sprague-Dawley rats were randomly divided into a sham group (n=10), a eugenol group (n=10 pairs, don
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c88499bf76126d1a6e6912e3f8c7692d
https://pubmed.ncbi.nlm.nih.gov/30233696
https://pubmed.ncbi.nlm.nih.gov/30233696
Autor:
Yi Chao Huang, Qianyi Xie
Publikováno v:
Journal of Intelligent Manufacturing
With relatively short latency and rapid propagation, viral diseases could be transmitted through the air to medical personnel or the public during the incubation period. To reduce the possibilities of spread, this research creates an infection probab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::724fd9d798952fc83070ad5a2061b52c
https://doi.org/10.1007/s10845-013-0796-0
https://doi.org/10.1007/s10845-013-0796-0
Autor:
Qianyi Xie
Publikováno v:
IOP Conference Series: Earth and Environmental Science. 6:232023
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54805904cbb9e0ac3e1cf871c1527a88
https://doi.org/10.1088/1755-1307/6/23/232023
https://doi.org/10.1088/1755-1307/6/23/232023
Autor:
Feng, Wei1 (AUTHOR), Jin, Longyu1 (AUTHOR), Xie, Qianyi1 (AUTHOR), Huang, Lihua2 (AUTHOR), Jiang, Zhibin1 (AUTHOR), Ji, Ying1 (AUTHOR), Li, Chunyun3 (AUTHOR), Yang, Linfei2 (AUTHOR), Wang, Dianjun1 (AUTHOR) wangdianjun5128@163.com
Publikováno v:
Experimental & Therapeutic Medicine. Oct2018, Vol. 16 Issue 4, p3464-3470. 7p.
Autor:
Guo, Ruiqi, Sui, Fanping, Yue, Wei, Wang, Zekai, Pala, Sedat, Li, Kunying, Xu, Renxiao, Lin, Liwei
Publikováno v:
Microsystems & Nanoengineering; 8/29/2022, Vol. 8 Issue 1, p1-10, 10p
Autor:
Liu, Suo, Jiang, Zhibin, Xiao, Peng, Li, Xiaozhi, Chen, Yinji, Tang, Hao, Chai, Yanfei, Liu, Yicai, Zhu, Zhao, Xie, Qianyi, He, Wei, Ma, Yuchao, Jin, Longyu, Feng, Wei
Publikováno v:
Cancer Science; Jan2022, Vol. 113 Issue 1, p79-90, 12p